<i>Conclusions</i>: HER3 expression was associated with reduced first-line TKI efficacy in EGFR-mutant NSCLC, suggesting a possible role for HER3 in primary TKI resistance; however, these findings are exploratory and did not reach statistical significance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.